Global Neurometabolic Disorders Market Size, Status and Forecast 2024-2031

Report ID: 933572 | Published Date: Sep 2024 | No. of Page: 120 | Base Year: 2023 | Rating: 4.3 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Neurometabolic Disorders Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Gaucher’s Disease
        1.2.3 Fabry Disease
        1.2.4 Pompe Disease
        1.2.5 Mucopolysaccharidosis VI
        1.2.6 Other
    1.3 Market by Application
        1.3.1 Global Neurometabolic Disorders Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Oral
        1.3.3 Parenteral
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Neurometabolic Disorders Market Perspective (2016-2027)
    2.2 Neurometabolic Disorders Growth Trends by Regions
        2.2.1 Neurometabolic Disorders Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Neurometabolic Disorders Historic Market Share by Regions (2016-2021)
        2.2.3 Neurometabolic Disorders Forecasted Market Size by Regions (2022-2027)
    2.3 Neurometabolic Disorders Industry Dynamic
        2.3.1 Neurometabolic Disorders Market Trends
        2.3.2 Neurometabolic Disorders Market Drivers
        2.3.3 Neurometabolic Disorders Market Challenges
        2.3.4 Neurometabolic Disorders Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Neurometabolic Disorders Players by Revenue
        3.1.1 Global Top Neurometabolic Disorders Players by Revenue (2016-2021)
        3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2016-2021)
    3.2 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Neurometabolic Disorders Revenue
    3.4 Global Neurometabolic Disorders Market Concentration Ratio
        3.4.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Neurometabolic Disorders Revenue in 2020
    3.5 Neurometabolic Disorders Key Players Head office and Area Served
    3.6 Key Players Neurometabolic Disorders Product Solution and Service
    3.7 Date of Enter into Neurometabolic Disorders Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Neurometabolic Disorders Breakdown Data by Type
    4.1 Global Neurometabolic Disorders Historic Market Size by Type (2016-2021)
    4.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2022-2027)

5 Neurometabolic Disorders Breakdown Data by Application
    5.1 Global Neurometabolic Disorders Historic Market Size by Application (2016-2021)
    5.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Neurometabolic Disorders Market Size (2016-2027)
    6.2 North America Neurometabolic Disorders Market Size by Type
        6.2.1 North America Neurometabolic Disorders Market Size by Type (2016-2021)
        6.2.2 North America Neurometabolic Disorders Market Size by Type (2022-2027)
        6.2.3 North America Neurometabolic Disorders Market Size by Type (2016-2027)
    6.3 North America Neurometabolic Disorders Market Size by Application
        6.3.1 North America Neurometabolic Disorders Market Size by Application (2016-2021)
        6.3.2 North America Neurometabolic Disorders Market Size by Application (2022-2027)
        6.3.3 North America Neurometabolic Disorders Market Size by Application (2016-2027)
    6.4 North America Neurometabolic Disorders Market Size by Country
        6.4.1 North America Neurometabolic Disorders Market Size by Country (2016-2021)
        6.4.2 North America Neurometabolic Disorders Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Neurometabolic Disorders Market Size (2016-2027)
    7.2 Europe Neurometabolic Disorders Market Size by Type
        7.2.1 Europe Neurometabolic Disorders Market Size by Type (2016-2021)
        7.2.2 Europe Neurometabolic Disorders Market Size by Type (2022-2027)
        7.2.3 Europe Neurometabolic Disorders Market Size by Type (2016-2027)
    7.3 Europe Neurometabolic Disorders Market Size by Application
        7.3.1 Europe Neurometabolic Disorders Market Size by Application (2016-2021)
        7.3.2 Europe Neurometabolic Disorders Market Size by Application (2022-2027)
        7.3.3 Europe Neurometabolic Disorders Market Size by Application (2016-2027)
    7.4 Europe Neurometabolic Disorders Market Size by Country
        7.4.1 Europe Neurometabolic Disorders Market Size by Country (2016-2021)
        7.4.2 Europe Neurometabolic Disorders Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Neurometabolic Disorders Market Size (2016-2027)
    8.2 Asia-Pacific Neurometabolic Disorders Market Size by Type
        8.2.1 Asia-Pacific Neurometabolic Disorders Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Neurometabolic Disorders Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Neurometabolic Disorders Market Size by Type (2016-2027)
    8.3 Asia-Pacific Neurometabolic Disorders Market Size by Application
        8.3.1 Asia-Pacific Neurometabolic Disorders Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Neurometabolic Disorders Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Neurometabolic Disorders Market Size by Application (2016-2027)
    8.4 Asia-Pacific Neurometabolic Disorders Market Size by Region
        8.4.1 Asia-Pacific Neurometabolic Disorders Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Neurometabolic Disorders Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Neurometabolic Disorders Market Size (2016-2027)
    9.2 Latin America Neurometabolic Disorders Market Size by Type
        9.2.1 Latin America Neurometabolic Disorders Market Size by Type (2016-2021)
        9.2.2 Latin America Neurometabolic Disorders Market Size by Type (2022-2027)
        9.2.3 Latin America Neurometabolic Disorders Market Size by Type (2016-2027)
    9.3 Latin America Neurometabolic Disorders Market Size by Application
        9.3.1 Latin America Neurometabolic Disorders Market Size by Application (2016-2021)
        9.3.2 Latin America Neurometabolic Disorders Market Size by Application (2022-2027)
        9.3.3 Latin America Neurometabolic Disorders Market Size by Application (2016-2027)
    9.4 Latin America Neurometabolic Disorders Market Size by Country
        9.4.1 Latin America Neurometabolic Disorders Market Size by Country (2016-2021)
        9.4.2 Latin America Neurometabolic Disorders Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Neurometabolic Disorders Market Size (2016-2027)
    10.2 Middle East & Africa Neurometabolic Disorders Market Size by Type
        10.2.1 Middle East & Africa Neurometabolic Disorders Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Neurometabolic Disorders Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Neurometabolic Disorders Market Size by Type (2016-2027)
    10.3 Middle East & Africa Neurometabolic Disorders Market Size by Application
        10.3.1 Middle East & Africa Neurometabolic Disorders Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Neurometabolic Disorders Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Neurometabolic Disorders Market Size by Application (2016-2027)
    10.4 Middle East & Africa Neurometabolic Disorders Market Size by Country
        10.4.1 Middle East & Africa Neurometabolic Disorders Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Neurometabolic Disorders Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Amicus Therapeutics
        11.1.1 Amicus Therapeutics Company Details
        11.1.2 Amicus Therapeutics Business Overview
        11.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction
        11.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2016-2021)
        11.1.5 Amicus Therapeutics Recent Development
    11.2 ISU Abxis
        11.2.1 ISU Abxis Company Details
        11.2.2 ISU Abxis Business Overview
        11.2.3 ISU Abxis Neurometabolic Disorders Introduction
        11.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2016-2021)
        11.2.5 ISU Abxis Recent Development
    11.3 JCR Pharmaceuticals
        11.3.1 JCR Pharmaceuticals Company Details
        11.3.2 JCR Pharmaceuticals Business Overview
        11.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction
        11.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021)
        11.3.5 JCR Pharmaceuticals Recent Development
    11.4 Biosidus
        11.4.1 Biosidus Company Details
        11.4.2 Biosidus Business Overview
        11.4.3 Biosidus Neurometabolic Disorders Introduction
        11.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2016-2021)
        11.4.5 Biosidus Recent Development
    11.5 Greenovation Biotech
        11.5.1 Greenovation Biotech Company Details
        11.5.2 Greenovation Biotech Business Overview
        11.5.3 Greenovation Biotech Neurometabolic Disorders Introduction
        11.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2016-2021)
        11.5.5 Greenovation Biotech Recent Development
    11.6 UAB Proforma
        11.6.1 UAB Proforma Company Details
        11.6.2 UAB Proforma Business Overview
        11.6.3 UAB Proforma Neurometabolic Disorders Introduction
        11.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2016-2021)
        11.6.5 UAB Proforma Recent Development
    11.7 Dong-A Socio Group
        11.7.1 Dong-A Socio Group Company Details
        11.7.2 Dong-A Socio Group Business Overview
        11.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction
        11.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2016-2021)
        11.7.5 Dong-A Socio Group Recent Development
    11.8 ExSAR Corporation
        11.8.1 ExSAR Corporation Company Details
        11.8.2 ExSAR Corporation Business Overview
        11.8.3 ExSAR Corporation Neurometabolic Disorders Introduction
        11.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2016-2021)
        11.8.5 ExSAR Corporation Recent Development
    11.9 Lixte Biotechnology
        11.9.1 Lixte Biotechnology Company Details
        11.9.2 Lixte Biotechnology Business Overview
        11.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction
        11.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2016-2021)
        11.9.5 Lixte Biotechnology Recent Development
    11.10 Neuraltus Pharmaceuticals
        11.10.1 Neuraltus Pharmaceuticals Company Details
        11.10.2 Neuraltus Pharmaceuticals Business Overview
        11.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction
        11.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021)
        11.10.5 Neuraltus Pharmaceuticals Recent Development
    11.11 Protalix
        11.11.1 Protalix Company Details
        11.11.2 Protalix Business Overview
        11.11.3 Protalix Neurometabolic Disorders Introduction
        11.11.4 Protalix Revenue in Neurometabolic Disorders Business (2016-2021)
        11.11.5 Protalix Recent Development
    11.12 Pharming Group
        11.12.1 Pharming Group Company Details
        11.12.2 Pharming Group Business Overview
        11.12.3 Pharming Group Neurometabolic Disorders Introduction
        11.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2016-2021)
        11.12.5 Pharming Group Recent Development
    11.13 Protalix BioTherapeutics
        11.13.1 Protalix BioTherapeutics Company Details
        11.13.2 Protalix BioTherapeutics Business Overview
        11.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction
        11.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2016-2021)
        11.13.5 Protalix BioTherapeutics Recent Development
    11.14 Amicus
        11.14.1 Amicus Company Details
        11.14.2 Amicus Business Overview
        11.14.3 Amicus Neurometabolic Disorders Introduction
        11.14.4 Amicus Revenue in Neurometabolic Disorders Business (2016-2021)
        11.14.5 Amicus Recent Development
    11.15 Biomarin
        11.15.1 Biomarin Company Details
        11.15.2 Biomarin Business Overview
        11.15.3 Biomarin Neurometabolic Disorders Introduction
        11.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2016-2021)
        11.15.5 Biomarin Recent Development
    11.16 Genzyme
        11.16.1 Genzyme Company Details
        11.16.2 Genzyme Business Overview
        11.16.3 Genzyme Neurometabolic Disorders Introduction
        11.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2016-2021)
        11.16.5 Genzyme Recent Development
    11.17 Shire
        11.17.1 Shire Company Details
        11.17.2 Shire Business Overview
        11.17.3 Shire Neurometabolic Disorders Introduction
        11.17.4 Shire Revenue in Neurometabolic Disorders Business (2016-2021)
        11.17.5 Shire Recent Development
    11.18 Greencross
        11.18.1 Greencross Company Details
        11.18.2 Greencross Business Overview
        11.18.3 Greencross Neurometabolic Disorders Introduction
        11.18.4 Greencross Revenue in Neurometabolic Disorders Business (2016-2021)
        11.18.5 Greencross Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Neurometabolic Disorders Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Gaucher’s Disease
    Table 3. Key Players of Fabry Disease
    Table 4. Key Players of Pompe Disease
    Table 5. Key Players of Mucopolysaccharidosis VI
    Table 6. Key Players of Other
    Table 7. Global Neurometabolic Disorders Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Neurometabolic Disorders Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 9. Global Neurometabolic Disorders Market Size by Regions (2016-2021) & (US$ Million)
    Table 10. Global Neurometabolic Disorders Market Share by Regions (2016-2021)
    Table 11. Global Neurometabolic Disorders Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 12. Global Neurometabolic Disorders Market Share by Regions (2022-2027)
    Table 13. Neurometabolic Disorders Market Trends
    Table 14. Neurometabolic Disorders Market Drivers
    Table 15. Neurometabolic Disorders Market Challenges
    Table 16. Neurometabolic Disorders Market Restraints
    Table 17. Global Neurometabolic Disorders Revenue by Players (2016-2021) & (US$ Million)
    Table 18. Global Neurometabolic Disorders Market Share by Players (2016-2021)
    Table 19. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurometabolic Disorders as of 2020)
    Table 20. Ranking of Global Top Neurometabolic Disorders Companies by Revenue (US$ Million) in 2020
    Table 21. Global 5 Largest Players Market Share by Neurometabolic Disorders Revenue (CR5 and HHI) & (2016-2021)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Neurometabolic Disorders Product Solution and Service
    Table 24. Date of Enter into Neurometabolic Disorders Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
    Table 27. Global Neurometabolic Disorders Revenue Market Share by Type (2016-2021)
    Table 28. Global Neurometabolic Disorders Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 29. Global Neurometabolic Disorders Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 30. Global Neurometabolic Disorders Market Size Share by Application (2016-2021) & (US$ Million)
    Table 31. Global Neurometabolic Disorders Revenue Market Share by Application (2016-2021)
    Table 32. Global Neurometabolic Disorders Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 33. Global Neurometabolic Disorders Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 34. North America Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
    Table 35. North America Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
    Table 36. North America Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
    Table 37. North America Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
    Table 38. North America Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million) 
    Table 39. North America Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million) 
    Table 40. Europe Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
    Table 41. Europe Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
    Table 42. Europe Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
    Table 43. Europe Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
    Table 44. Europe Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million) 
    Table 45. Europe Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million) 
    Table 46. Asia-Pacific Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
    Table 49. Asia-Pacific Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
    Table 50. Asia-Pacific Neurometabolic Disorders Market Size by Region (2016-2021) & (US$ Million) 
    Table 51. Asia-Pacific Neurometabolic Disorders Market Size by Region (2022-2027) & (US$ Million) 
    Table 52. Latin America Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
    Table 53. Latin America Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
    Table 54. Latin America Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
    Table 55. Latin America Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
    Table 56. Latin America Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million) 
    Table 57. Latin America Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million) 
    Table 58. Middle East & Africa Neurometabolic Disorders Market Size by Type (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Neurometabolic Disorders Market Size by Type (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Neurometabolic Disorders Market Size by Application (2016-2021) (US$ Million)
    Table 61. Middle East & Africa Neurometabolic Disorders Market Size by Application (2022-2027) & (US$ Million)
    Table 62. Middle East & Africa Neurometabolic Disorders Market Size by Country (2016-2021) & (US$ Million) 
    Table 63. Middle East & Africa Neurometabolic Disorders Market Size by Country (2022-2027) & (US$ Million) 
    Table 64. Amicus Therapeutics Company Details
    Table 65. Amicus Therapeutics Business Overview
    Table 66. Amicus Therapeutics Neurometabolic Disorders Product
    Table 67. Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 68. Amicus Therapeutics Recent Development
    Table 69. ISU Abxis Company Details
    Table 70. ISU Abxis Business Overview
    Table 71. ISU Abxis Neurometabolic Disorders Product
    Table 72. ISU Abxis Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 73. ISU Abxis Recent Development
    Table 74. JCR Pharmaceuticals Company Details
    Table 75. JCR Pharmaceuticals Business Overview
    Table 76. JCR Pharmaceuticals Neurometabolic Disorders Product
    Table 77. JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 78. JCR Pharmaceuticals Recent Development
    Table 79. Biosidus Company Details
    Table 80. Biosidus Business Overview
    Table 81. Biosidus Neurometabolic Disorders Product
    Table 82. Biosidus Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 83. Biosidus Recent Development
    Table 84. Greenovation Biotech Company Details
    Table 85. Greenovation Biotech Business Overview
    Table 86. Greenovation Biotech Neurometabolic Disorders Product
    Table 87. Greenovation Biotech Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 88. Greenovation Biotech Recent Development
    Table 89. UAB Proforma Company Details
    Table 90. UAB Proforma Business Overview
    Table 91. UAB Proforma Neurometabolic Disorders Product
    Table 92. UAB Proforma Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 93. UAB Proforma Recent Development
    Table 94. Dong-A Socio Group Company Details
    Table 95. Dong-A Socio Group Business Overview
    Table 96. Dong-A Socio Group Neurometabolic Disorders Product
    Table 97. Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 98. Dong-A Socio Group Recent Development
    Table 99. ExSAR Corporation Company Details
    Table 100. ExSAR Corporation Business Overview
    Table 101. ExSAR Corporation Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 102. ExSAR Corporation Recent Development
    Table 103. Lixte Biotechnology Company Details
    Table 104. Lixte Biotechnology Business Overview
    Table 105. Lixte Biotechnology Neurometabolic Disorders Product
    Table 106. Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 107. Lixte Biotechnology Recent Development
    Table 108. Neuraltus Pharmaceuticals Company Details
    Table 109. Neuraltus Pharmaceuticals Business Overview
    Table 110. Neuraltus Pharmaceuticals Neurometabolic Disorders Product
    Table 111. Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 112. Neuraltus Pharmaceuticals Recent Development
    Table 113. Protalix Company Details
    Table 114. Protalix Business Overview
    Table 115. Protalix Neurometabolic Disorders Product
    Table 116. Protalix Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 117. Protalix Recent Development
    Table 118. Pharming Group Company Details
    Table 119. Pharming Group Business Overview
    Table 120. Pharming Group Neurometabolic Disorders Product
    Table 121. Pharming Group Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 122. Pharming Group Recent Development
    Table 123. Protalix BioTherapeutics Company Details
    Table 124. Protalix BioTherapeutics Business Overview
    Table 125. Protalix BioTherapeutics Neurometabolic Disorders Product
    Table 126. Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 127. Protalix BioTherapeutics Recent Development
    Table 128. Amicus Company Details
    Table 129. Amicus Business Overview
    Table 130. Amicus Neurometabolic Disorders Product
    Table 131. Amicus Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 132. Amicus Recent Development
    Table 133. Biomarin Company Details
    Table 134. Biomarin Business Overview
    Table 135. Biomarin Neurometabolic Disorders Product
    Table 136. Biomarin Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 137. Biomarin Recent Development
    Table 138. Genzyme Company Details
    Table 139. Genzyme Business Overview
    Table 140. Genzyme Neurometabolic Disorders Product
    Table 141. Genzyme Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 142. Genzyme Recent Development
    Table 143. Shire Company Details
    Table 144. Shire Business Overview
    Table 145. Shire Neurometabolic Disorders Product
    Table 146. Shire Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 147. Shire Recent Development
    Table 148. Greencross Company Details
    Table 149. Greencross Business Overview
    Table 150. Greencross Neurometabolic Disorders Product
    Table 151. Greencross Revenue in Neurometabolic Disorders Business (2016-2021) & (US$ Million)
    Table 152. Greencross Recent Development
    Table 153. Research Programs/Design for This Report
    Table 154. Key Data Information from Secondary Sources
    Table 155. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurometabolic Disorders Market Share by Type: 2020 VS 2027
    Figure 2. Gaucher’s Disease Features
    Figure 3. Fabry Disease Features
    Figure 4. Pompe Disease Features
    Figure 5. Mucopolysaccharidosis VI Features
    Figure 6. Other Features
    Figure 7. Global Neurometabolic Disorders Market Share by Application: 2020 VS 2027
    Figure 8. Oral Case Studies
    Figure 9. Parenteral Case Studies
    Figure 10. Neurometabolic Disorders Report Years Considered
    Figure 11. Global Neurometabolic Disorders Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 12. Global Neurometabolic Disorders Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Neurometabolic Disorders Market Share by Regions: 2020 VS 2027
    Figure 14. Global Neurometabolic Disorders Market Share by Regions (2022-2027)
    Figure 15. Global Neurometabolic Disorders Market Share by Players in 2020
    Figure 16. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurometabolic Disorders as of 2020
    Figure 17. The Top 10 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2020
    Figure 18. Global Neurometabolic Disorders Revenue Market Share by Type (2016-2021)
    Figure 19. Global Neurometabolic Disorders Revenue Market Share by Type (2022-2027)
    Figure 20. North America Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 21. North America Neurometabolic Disorders Market Share by Type (2016-2027)
    Figure 22. North America Neurometabolic Disorders Market Share by Application (2016-2027)
    Figure 23. North America Neurometabolic Disorders Market Share by Country (2016-2027)
    Figure 24. United States Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Canada Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Neurometabolic Disorders Market Share by Type (2016-2027)
    Figure 28. Europe Neurometabolic Disorders Market Share by Application (2016-2027)
    Figure 29. Europe Neurometabolic Disorders Market Share by Country (2016-2027)
    Figure 30. Germany Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. France Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. U.K. Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Italy Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Russia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Nordic Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Neurometabolic Disorders Market Share by Type (2016-2027)
    Figure 38. Asia-Pacific Neurometabolic Disorders Market Share by Application (2016-2027)
    Figure 39. Asia-Pacific Neurometabolic Disorders Market Share by Region (2016-2027)
    Figure 40. China Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Japan Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. South Korea Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Southeast Asia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. India Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Australia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Neurometabolic Disorders Market Share by Type (2016-2027)
    Figure 48. Latin America Neurometabolic Disorders Market Share by Application (2016-2027)
    Figure 49. Latin America Neurometabolic Disorders Market Share by Country (2016-2027)
    Figure 50. Mexico Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Brazil Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Neurometabolic Disorders Market Share by Type (2016-2027)
    Figure 54. Middle East & Africa Neurometabolic Disorders Market Share by Application (2016-2027)
    Figure 55. Middle East & Africa Neurometabolic Disorders Market Share by Country (2016-2027)
    Figure 56. Turkey Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Saudi Arabia Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. UAE Neurometabolic Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. Amicus Therapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 60. ISU Abxis Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 61. JCR Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 62. Biosidus Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 63. Greenovation Biotech Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 64. UAB Proforma Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 65. Dong-A Socio Group Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 66. ExSAR Corporation Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 67. Lixte Biotechnology Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 68. Neuraltus Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 69. Protalix Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 70. Pharming Group Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 71. Protalix BioTherapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 72. Amicus Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 73. Biomarin Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 74. Genzyme Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 75. Shire Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 76. Greencross Revenue Growth Rate in Neurometabolic Disorders Business (2016-2021)
    Figure 77. Bottom-up and Top-down Approaches for This Report
    Figure 78. Data Triangulation
    Figure 79. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Frequently Asked Questions
Neurometabolic Disorders report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neurometabolic Disorders report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neurometabolic Disorders report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Cloud Sandbox

Market Analysis and Insights: Global Cloud Sandbox Market
The global Cloud Sandbox  ... Read More

Electronic Payment

Electronic Payment is a payment solution which is made through digital modes with no hard cash. I ... Read More

Pico Solar Systems

Pico Solar Systems are becoming more common place with us using pico solar cells in our daily liv ... Read More